SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and ...

Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. AbbVie will pay ...

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...

SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another ...